Shun Iwai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shun Iwai has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Hidetaka Uramoto
Department of Thoracic Surgery, Kanazawa Medical University, Ishikawa, Japan
2 shared publications - Masahito Ishikawa
Department of Thoracic Surgery, Kanazawa Medical University, Ishikawa, Japan
2 shared publications - Nozomu Motono
Department of Thoracic Surgery, Kanazawa Medical University, Ishikawa, Japan
2 shared publications - Yoshihito Iijima
Department of Thoracic Surgery, Kanazawa Medical University, Ishikawa, Japan
2 shared publications - Akihiro Shioya
Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Uchinada, Japan
1 shared publication - Sohsuke Yamada
Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Uchinada 920-0293, Ishikawa, Japan
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.25-0677
Primary Gastric Adenocarcinoma with Thyroid Transcription Factor-1 Positivity Mimicking Gastric Metastasis from Lung Cancer: A Case Report
INTRODUCTION: Thyroid transcription factor-1 (TTF-1) is a well-established immunohistochemical marker for tumors of lung and thyroid origin. Metastatic adenocarcinomas are often tested for TTF-1 expression to identify their primary site. Herein, we report a rare case of TTF-1–positive primary gastric adenocarcinoma that was initially misdiagnosed and treated as postoperative gastric metastasis from primary lung cancer.CASE PRESENTATION: A 58-year-old man underwent thoracoscopic right upper lobectomy with systemic lymph node dissection for lung cancer of the right upper lobe. The pathological diagnosis was invasive adenocarcinoma (pT2bN0M0, Stage IIA). He received 3 courses of postoperative adjuvant platinum doublet chemotherapy. One year and 2 months after surgery, he was diagnosed with gastric and adrenal tumors. Immunohistochemical analysis of the gastric lesion demonstrated TTF-1 positivity, leading to the diagnosis of gastric and adrenal metastatic recurrence of lung cancer. The patient received triple therapy with carboplatin, pemetrexed, and pembrolizumab, followed by maintenance therapy with pemetrexed and pembrolizumab. During treatment, the adrenal metastasis achieved a complete response; however, the gastric lesion showed gradual progression on endoscopic follow-up. As primary gastric cancer could not be ruled out, the patient underwent robot-assisted distal gastrectomy with D2 lymph node dissection and Billroth I reconstruction, 3 years and 4 months following lung resection. Immunohistochemical staining of the gastric tumor revealed adenocarcinoma that was positive for TTF-1 and caudal-related homeodomain protein 2 (CDX2) and negative for napsin A. In contrast, lung cancer tissue was weakly positive for TTF-1 and negative for napsin A and CDX2. Based on the immunohistochemical staining and histological findings, the final diagnosis was primary gastric adenocarcinoma. The postoperative course was uneventful, and maintenance chemotherapy with pemetrexed and pembrolizumab was resumed. Four years and 10 months after cancer surgery, the patient remains in complete response.CONCLUSIONS: This case highlights the diagnostic challenge posed by TTF-1–positive gastric tumors, which may be mistaken for metastatic lesions from lung cancer. As TTF-1 expression is not entirely specific to tissues of lung or thyroid origin, diagnosis should be based on a comprehensive evaluation of morphological and immunohistochemical findings, together with clinical information, including treatment response and disease course.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.25-0677
Open AccessPrimary Gastric Adenocarcinoma with Thyroid Transcription Factor-1 Positivity Mimicking Gastric Metastasis from Lung Cancer: A Case Report
INTRODUCTION: Thyroid transcription factor-1 (TTF-1) is a well-established immunohistochemical marker for tumors of lung and thyroid origin. Metastatic adenocarcinomas are often tested for TTF-1 expression to identify their primary site. Herein, we report a rare case of TTF-1–positive primary gastric adenocarcinoma that was initially misdiagnosed and treated as postoperative gastric metastasis from primary lung cancer.CASE PRESENTATION: A 58-year-old man underwent thoracoscopic right upper lobectomy with systemic lymph node dissection for lung cancer of the right upper lobe. The pathological diagnosis was invasive adenocarcinoma (pT2bN0M0, Stage IIA). He received 3 courses of postoperative adjuvant platinum doublet chemotherapy. One year and 2 months after surgery, he was diagnosed with gastric and adrenal tumors. Immunohistochemical analysis of the gastric lesion demonstrated TTF-1 positivity, leading to the diagnosis of gastric and adrenal metastatic recurrence of lung cancer. The patient received triple therapy with carboplatin, pemetrexed, and pembrolizumab, followed by maintenance therapy with pemetrexed and pembrolizumab. During treatment, the adrenal metastasis achieved a complete response; however, the gastric lesion showed gradual progression on endoscopic follow-up. As primary gastric cancer could not be ruled out, the patient underwent robot-assisted distal gastrectomy with D2 lymph node dissection and Billroth I reconstruction, 3 years and 4 months following lung resection. Immunohistochemical staining of the gastric tumor revealed adenocarcinoma that was positive for TTF-1 and caudal-related homeodomain protein 2 (CDX2) and negative for napsin A. In contrast, lung cancer tissue was weakly positive for TTF-1 and negative for napsin A and CDX2. Based on the immunohistochemical staining and histological findings, the final diagnosis was primary gastric adenocarcinoma. The postoperative course was uneventful, and maintenance chemotherapy with pemetrexed and pembrolizumab was resumed. Four years and 10 months after cancer surgery, the patient remains in complete response.CONCLUSIONS: This case highlights the diagnostic challenge posed by TTF-1–positive gastric tumors, which may be mistaken for metastatic lesions from lung cancer. As TTF-1 expression is not entirely specific to tissues of lung or thyroid origin, diagnosis should be based on a comprehensive evaluation of morphological and immunohistochemical findings, together with clinical information, including treatment response and disease course.
- Open Access
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.25-0642
Immune Thrombocytopenia Successfully Controlled by Dissection of an Enlarged Mediastinal Lymph Node Metastasis from Squamous Cell Carcinoma of Unknown Primary: A Case Report
INTRODUCTION: Immune thrombocytopenia (ITP) is an autoimmune hematologic disorder characterized by a reduced platelet count resulting from immune-mediated platelet destruction and/or impaired thrombopoiesis. This condition is often associated with malignant tumors, making perioperative management crucial to maintain hemostasis during and after surgery. Herein, we report a case of ITP successfully controlled following surgical dissection of a large mediastinal lymph node metastasis originating from squamous cell carcinoma of unknown primary.CASE PRESENTATION: A 57-year-old man with poorly controlled ITP was found to have progressively enlarging mediastinal lymph nodes on chest CT over 4 months. The largest lymph node measured 72× 37× 31 mm. The patient received preoperative intravenous immunoglobulin therapy (0.4 g/kg/day) for 4 days, after which mediastinal lymph node dissection was safely performed without hemorrhagic complications. The platelet count improved transiently after surgery. Histopathology revealed metastatic poorly differentiated squamous cell carcinoma, but imaging failed to identify a primary lesion, leading to a diagnosis of squamous cell carcinoma of unknown primary.CONCLUSIONS: With appropriate preoperative management, the platelet count was effectively controlled, allowing safe removal of the large mediastinal lymph node. As the platelet level improved postoperatively, prednisolone tapering was initiated. Given that recurrent malignancy may precipitate a decline in platelet count, close follow-up is warranted.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.25-0642
Open AccessImmune Thrombocytopenia Successfully Controlled by Dissection of an Enlarged Mediastinal Lymph Node Metastasis from Squamous Cell Carcinoma of Unknown Primary: A Case Report
INTRODUCTION: Immune thrombocytopenia (ITP) is an autoimmune hematologic disorder characterized by a reduced platelet count resulting from immune-mediated platelet destruction and/or impaired thrombopoiesis. This condition is often associated with malignant tumors, making perioperative management crucial to maintain hemostasis during and after surgery. Herein, we report a case of ITP successfully controlled following surgical dissection of a large mediastinal lymph node metastasis originating from squamous cell carcinoma of unknown primary.CASE PRESENTATION: A 57-year-old man with poorly controlled ITP was found to have progressively enlarging mediastinal lymph nodes on chest CT over 4 months. The largest lymph node measured 72× 37× 31 mm. The patient received preoperative intravenous immunoglobulin therapy (0.4 g/kg/day) for 4 days, after which mediastinal lymph node dissection was safely performed without hemorrhagic complications. The platelet count improved transiently after surgery. Histopathology revealed metastatic poorly differentiated squamous cell carcinoma, but imaging failed to identify a primary lesion, leading to a diagnosis of squamous cell carcinoma of unknown primary.CONCLUSIONS: With appropriate preoperative management, the platelet count was effectively controlled, allowing safe removal of the large mediastinal lymph node. As the platelet level improved postoperatively, prednisolone tapering was initiated. Given that recurrent malignancy may precipitate a decline in platelet count, close follow-up is warranted.